Literature DB >> 24806703

Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.

Jonathan A Cook1, Jennifer Hislop1, Temitope E Adewuyi1, Kirsten Harrild2, Douglas G Altman3, Craig R Ramsay1, Cynthia Fraser1, Brian Buckley4, Peter Fayers5, Ian Harvey6, Andrew H Briggs7, John D Norrie1, Dean Fergusson8, Ian Ford9, Luke D Vale10.   

Abstract

BACKGROUND: The randomised controlled trial (RCT) is widely considered to be the gold standard study for comparing the effectiveness of health interventions. Central to the design and validity of a RCT is a calculation of the number of participants needed (the sample size). The value used to determine the sample size can be considered the 'target difference'. From both a scientific and an ethical standpoint, selecting an appropriate target difference is of crucial importance. Determination of the target difference, as opposed to statistical approaches to calculating the sample size, has been greatly neglected though a variety of approaches have been proposed the current state of the evidence is unclear.
OBJECTIVES: The aim was to provide an overview of the current evidence regarding specifying the target difference in a RCT sample size calculation. The specific objectives were to conduct a systematic review of methods for specifying a target difference; to evaluate current practice by surveying triallists; to develop guidance on specifying the target difference in a RCT; and to identify future research needs.
DESIGN: The biomedical and social science databases searched were MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology Register, PsycINFO, Science Citation Index, EconLit, Education Resources Information Center (ERIC) and Scopus for in-press publications. All were searched from 1966 or the earliest date of the database coverage and searches were undertaken between November 2010 and January 2011. There were three interlinked components: (1) systematic review of methods for specifying a target difference for RCTs - a comprehensive search strategy involving an electronic literature search of biomedical and some non-biomedical databases and clinical trials textbooks was carried out; (2) identification of current trial practice using two surveys of triallists - members of the Society for Clinical Trials (SCT) were invited to complete an online survey and respondents were asked about their awareness and use of, and willingness to recommend, methods; one individual per triallist group [UK Clinical Research Collaboration (UKCRC)-registered Clinical Trials Units (CTUs), Medical Research Council (MRC) UK Hubs for Trials Methodology Research and National Institute for Health Research (NIHR) UK Research Design Services (RDS)] was invited to complete a survey; (3) production of a structured guidance document to aid the design of future trials - the draft guidance was developed utilising the results of the systematic review and surveys by the project steering and advisory groups.
SETTING: Methodological review incorporating electronic searches, review of books and guidelines, two surveys of experts (membership of an international society and UK- and Ireland-based triallists) and development of guidance. PARTICIPANTS: The two surveys were sent out to membership of the SCT and UK- and Ireland-based triallists.
INTERVENTIONS: The review focused on methods for specifying the target difference in a RCT. It was not restricted to any type of intervention or condition. MAIN OUTCOME MEASURES: Methods for specifying the target difference for a RCT were considered.
RESULTS: The search identified 11,485 potentially relevant studies. In total, 1434 were selected for full-text assessment and 777 were included in the review. Seven methods to specify the target difference for a RCT were identified - anchor, distribution, health economic, opinion-seeking, pilot study, review of evidence base (RoEB) and standardised effect size (SES) - each having important variations in implementation. A total of 216 of the included studies used more than one method. A total of 180 (15%) responses to the SCT survey were received, representing 13 countries. Awareness of methods ranged from 38% (n =69) for the health economic method to 90% (n =162) for the pilot study. Of the 61 surveys sent out to UK triallist groups, 34 (56%) responses were received. Awareness ranged from 97% (n =33) for the RoEB and pilot study methods to only 41% (n =14) for the distribution method. Based on the most recent trial, all bar three groups (91%, n =30) used a formal method. Guidance was developed on the use of each method and the reporting of the sample size calculation in a trial protocol and results paper.
CONCLUSIONS: There is a clear need for greater use of formal methods to determine the target difference and better reporting of its specification. Raising the standard of RCT sample size calculations and the corresponding reporting of them would aid health professionals, patients, researchers and funders in judging the strength of the evidence and ensuring better use of scarce resources. FUNDING: The Medical Research Council UK and the National Institute for Health Research Joint Methodology Research programme.

Entities:  

Mesh:

Year:  2014        PMID: 24806703      PMCID: PMC4781097          DOI: 10.3310/hta18280

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  31 in total

Review 1.  Design characteristic of randomised controlled trials for geographic atrophy in age-related macular degeneration: selection of outcomes and sample size calculation.

Authors:  A K Krezel; R E Hogg; S Krezel; R Fallis; A Azuara-Blanco
Journal:  Eye (Lond)       Date:  2015-07-24       Impact factor: 3.775

Review 2.  Basic statistical considerations for physiology: The journal Temperature toolbox.

Authors:  Aaron R Caldwell; Samuel N Cheuvront
Journal:  Temperature (Austin)       Date:  2019-06-25

3.  Cross-Center Virtual Education Fellowship Program for Early-Career Researchers in Atrial Fibrillation.

Authors:  Tinuola B Ajayi; Christy D Remein; Ellen Childs; Emelia J Benjamin; Randall S Stafford; Angela Fagerlin; Mina K Chung
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-10-08

4.  Error Rates, Decisive Outcomes and Publication Bias with Several Inferential Methods.

Authors:  Will G Hopkins; Alan M Batterham
Journal:  Sports Med       Date:  2016-10       Impact factor: 11.136

5.  Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers.

Authors:  Jonathan A Cook; Jenni Hislop; Douglas G Altman; Peter Fayers; Andrew H Briggs; Craig R Ramsay; John D Norrie; Ian M Harvey; Brian Buckley; Dean Fergusson; Ian Ford; Luke D Vale
Journal:  Trials       Date:  2015-01-15       Impact factor: 2.279

6.  Ophthalmic statistics note 6: effect sizes matter.

Authors:  Jonathan A Cook; Catey Bunce; Caroline J Doré; Nick Freemantle
Journal:  Br J Ophthalmol       Date:  2015-02-26       Impact factor: 4.638

7.  A mixed methods study to assess the feasibility of a randomised controlled trial of invasive urodynamic testing versus clinical assessment and non-invasive tests prior to surgery for stress urinary incontinence in women: the INVESTIGATE-I study.

Authors:  Paul Hilton; Natalie Armstrong; Catherine Brennand; Denise Howel; Jing Shen; Andrew Bryant; Douglas G Tincello; Malcolm G Lucas; Brian S Buckley; Christopher R Chapple; Tara Homer; Luke Vale; Elaine McColl
Journal:  Trials       Date:  2015-09-08       Impact factor: 2.279

Review 8.  Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?

Authors:  Christopher J Yarnell; Darryl Abrams; Matthew R Baldwin; Daniel Brodie; Eddy Fan; Niall D Ferguson; May Hua; Purnema Madahar; Danny F McAuley; Laveena Munshi; Gavin D Perkins; Gordon Rubenfeld; Arthur S Slutsky; Hannah Wunsch; Robert A Fowler; George Tomlinson; Jeremy R Beitler; Ewan C Goligher
Journal:  Lancet Respir Med       Date:  2020-11-20       Impact factor: 30.700

Review 9.  Artificial intelligence extension of the OSCAR-IB criteria.

Authors:  Axel Petzold; Philipp Albrecht; Laura Balcer; Erik Bekkers; Alexander U Brandt; Peter A Calabresi; Orla Galvin Deborah; Jennifer S Graves; Ari Green; Pearse A Keane; Jenny A Nij Bijvank; Josemir W Sander; Friedemann Paul; Shiv Saidha; Pablo Villoslada; Siegfried K Wagner; E Ann Yeh
Journal:  Ann Clin Transl Neurol       Date:  2021-05-19       Impact factor: 4.511

10.  Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the United Kingdom?

Authors:  Jennifer Burr; Rodolfo Hernández; Craig Ramsay; Maria Prior; Susan Campbell; Augusto Azuara-Blanco; Marion Campbell; Jill Francis; Luke Vale
Journal:  J Health Serv Res Policy       Date:  2013-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.